Posts By: Action Radiotherapy

Adding radiotherapy to chemotherapy may dramatically improve survival for advanced-stage NSCLC patients

Combining radiotherapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomised phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO). Markets Insider

Long-term survival rates more than double previous estimates for locally advanced lung cancer

Long-term results of a phase III clinical trial indicate that survival rates for patients receiving chemo-radiotherapy for un-resectable, locally advanced non-small cell lung cancer may be more than twice as high as previous estimates. Findings will be presented at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. PRNewswire

Qfix® launches new radiotherapy positioning technology for the more precise treatment of breast cancer

Qfix announced the release of the first-in-its-class kVue™ Access 360™ G2 and Access™ Prone G2 positioning devices that promise to improve prone breast cancer treatment by significantly reducing radiotherapy dose to healthy tissue while improving patient comfort and reproducible positioning. Markets Insider – Comment on this story

Chemotherapy followed by consolidative proton therapy achieves encouraging relapse free survival rates in patients with newly diagnosed Hodgkin Lymphoma

Researchers concluded that consolidated proton therapy following standard chemotherapy in Hodgkin Lymphoma is primarily used in young patients with mediastinal and bulky disease. Early relapse-free survival rates are similar to those reported with photon radiation treatment, and no early grade 3 toxicities have been observed. Lymphomahub